The engineered endolysin PM-477 demonstrated a significant ability to kill Gardnerella species and dissolve biofilms in 14 out of 15 tested cases of bacterial vaginosis, without affecting the remaining healthy vaginal microbiome. This suggests a promising alternative to antibiotics for treating BV, particularly in patients with recurrent infections.
The study demonstrated that drug combinations showed synergistic effects on the sensitivity of Candida isolates, providing a more effective alternative to monotherapy and addressing drug resistance issues.
92.74% of participants rated the clinical performance of Halova ovules as 'excellent' when used alone, and 95.71% when used with other medications, with significant reductions in vaginal dryness and dyspareunia.
Cerviron ovules demonstrated effectiveness in relieving vaginal symptoms and restoring normal vaginal pH levels after 3 months of treatment, both as a standalone treatment and in conjunction with antibiotics.
Astodrimer 1% Gel was superior to placebo in preventing recurrence of bacterial vaginosis, with a lower recurrence rate (44.2% vs 54.3%) and longer time to recurrence. Subject-reported symptoms such as vaginal odor and discharge were also significantly lower in the Astodrimer group.